25 February 2021
Geneva – The Medicines Patent Pool (MPP) and the World Intellectual Property Organization (WIPO) strengthen collaboration in areas including intellectual property management strategies, information sharing, and capacity building, in order to advance the United Nations 2030 Agenda for Sustainable Development.
“WIPO has been an instrumental partner of MPP throughout the years and today we are delighted to better articulate our collaboration and bring it to the next level,” says Charles Gore, Executive Director of MPP. “Gathering and sharing knowledge and patent information is essential, one example of which is the collaboration over the years in collecting patent data on essential medicines. We are looking forward to closer engagement, including on intellectual property management strategies for COVID-19 treatments and technologies.”
“We look forward to joining WIPO’s expertise in Intellectual Property and innovation to the MPP’s efforts to increase access to, and facilitate the development of, life-saving medicines for low-and middle-income countries,” said Amy Dietterich, Director of WIPO’s Global Challenges Division. “This collaboration aligns perfectly with WIPO’s central mission of leading the development of a balanced and effective international IP system that enables innovation and creativity for the benefit of all.”
The two parties agree to work together in different fields including intellectual property management strategies, information sharing and capacity building. The main areas of cooperation include:
i). Facilitating innovation and access to health technologies for COVID-19 by:
ii). Promoting patent transparency and the collection of patent information on essential medicines, by
iii). Collaborating on licensing and technology transfer by:
iv). Sharing information at the WIPO Standing Committee on the Law of Patents (SCP):
v). Exploring potential synergies between the two organisations activities to support early-stage research and development (R&D) in the fight against neglected tropical diseases (NTDs), malaria, and tuberculosis by:
vi). Exploring ways in which dispute resolution provisions may be further incorporated in MPP agreements.
WIPO was recently invited by MPP’s Governance Board to join board meetings as a non-voting observer, a status shared by others including the World Health Organization (WHO). WIPO is currently represented by Ms. Dietterich.
Press and Media
Partners
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada, the World Intellectual Property Organization (WIPO) and the Government of Flanders. MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.